Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,152 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Experimental Clear all
Completed Phase 1Phase 2 Interventional Results available

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

NCT03459222
View directory record Official record
Conditions
Advanced Cancer
Interventions
Relatlimab, Nivolumab, BMS-986205, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions

NCT01641237
View directory record Official record
Conditions
Enamel Erosion
Interventions
sodium fluoride, no added fluoride in a silica base
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03030885
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
131I-MIP-1095
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

NCT03660436
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986165, MMF
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System (ISO/FDA Study)

NCT02150109
View directory record Official record
Conditions
Diabetes
Interventions
Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS, Subjects WITH Diabetes Use Karajishi Contour BGMS
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 6, 2026, 11:07 AM EDT
Terminated Phase 1 Interventional Results available

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

NCT02551055
View directory record Official record
Conditions
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
Interventions
MLN1117, TAK-659, Alisertib, Paclitaxel, Docetaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Lake Success, New York • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

NCT02678416
View directory record Official record
Conditions
Pain
Interventions
IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D)
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 2 Interventional

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

NCT00044876
View directory record Official record
Conditions
Leiomyoma
Interventions
CDB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
33 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dispensing Evaluation of Investigational Contact Lenses

NCT02625220
View directory record Official record
Conditions
Myopia; Astigmatism
Interventions
Prototype toric lens senofilcon A
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
12
States / cities
Jacksonville, Florida • Pembroke Pines, Florida • Winter Park, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 6, 2026, 11:07 AM EDT
Completed No phase listed Observational

Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials

NCT00949390
View directory record Official record
Conditions
Advanced Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 6, 2026, 11:07 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

NCT04589624
View directory record Official record
Conditions
Thyroid Gland Carcinoma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

NCT04369391
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856 150 mg, Placebo, moxifloxacin 400 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Little Rock, Arkansas • Long Beach, California • Pico Rivera, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 6, 2026, 11:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Spatiotemporal Thalamocortical Alterations Underlie Experimental and Chronic Pain

NCT06968689
View directory record Official record
Conditions
Pain
Interventions
transcranial alternating current stimulation (tACS), Sham, transcranial random noise stimulation (tRNS)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

NCT00363142
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
Half-boosted Fosamprenavir, Full Boosted Fosamprenavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 4 Interventional Results available

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine

NCT01118273
View directory record Official record
Conditions
Sleep
Interventions
Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 440 mg (BAYH6689), Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 220 mg (BAYH6689), DPH 50mg, Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection

NCT00514605
View directory record Official record
Conditions
HIV Infections
Interventions
Behavioral counseling, HIV-1 Antibody Test Kit
Other · Device
Lead sponsor
bioLytical Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
14
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 6, 2026, 11:07 AM EDT
Recruiting Phase 1 Interventional

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562
View directory record Official record
Conditions
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions
CGT4255
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Not applicable Interventional Results available

Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System

NCT02041286
View directory record Official record
Conditions
Diabetes
Interventions
Karajishi Contour Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

NCT00061620
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Tezacitabine (FMdC)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 1 Interventional

This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.

NCT05015673
View directory record Official record
Conditions
Narcolepsy
Interventions
SEP363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 6, 2026, 11:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
Biological · Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Sep 6, 2026, 11:07 AM EDT
Recruiting Phase 1 Interventional

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267
View directory record Official record
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 6, 2026, 11:07 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Nicotine Pouch Pharmacokinetics Abuse Liability

NCT07476144
View directory record Official record
Conditions
Smoking Behaviors
Interventions
Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions.
Drug
Lead sponsor
JT International SA
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 6, 2026, 11:07 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Personalized Antisense Oligonucleotide for A Single Participant With UBTF Gene Mutation

NCT07588581
View directory record Official record
Conditions
Childhood-Onset Neurodegeneration With Brain Atrophy (CONDBA)
Interventions
nL-UBTF-001
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 6, 2026, 11:07 AM EDT